Clinical Trial Update: Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating safety, efficacy, and tolerability of NBI-827104 for essential tremor has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Tremor

Drugs mentioned

• NBI-827104

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Essential Tremor | Phase 2 | Status: COMPLETED